Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European …

Genomic events associated with poor outcome in chronic myeloid leukemia (CML) are
poorly understood. We performed whole-exome sequencing, copy-number variation, and/or …

The prognostic relevance of additional cytogenetic findings at diagnosis of chronic myeloid
leukemia (CML) is unclear. The impact of additional cytogenetic findings at diagnosis on …

This population-based registry was designed to provide robust and updated information on
the characteristics and the epidemiology of chronic myeloid leukemia (CML). All cases of …

Therapies that target BCR-ABL in chronic myeloid leukemia, including imatinib, dasatinib
and nilotinib, have dramatically improved patient outcome. BCR-ABL mutations, however …

Additional chromosomal abnormalities (ACAs) in Philadelphia-positive cells have been
reported in∼ 5% of patients with newly diagnosed chronic myeloid leukemia (CML) in …

Abstract Variant Philadelphia (Ph) chromosome translocations have been reported in 5%-
10% of patients with newly diagnosed chronic myeloid leukemia (CML). Variant …

Additional cytogenetic abnormalities (ACA) are considered a high risk feature in chronic
myeloid leukemia (CML). However, its prognostic significance at the time of diagnosis in the …

Chronic myeloid leukemia (CML) is characterized by the presence of BCR-ABL1 fusion
gene. In over 95% of CML patients, the typical BCR-ABL1 transcript subtypes are e13a2 …

Simple Summary Chronic myeloid leukemia (CML) is a blood cancer currently well
managed with drugs that inhibit the protein responsible for the disease. However, some …